In OCC 2026 Quest for Truth roundtable, leading cardiovascular experts from China and Australia gather to discuss “Hypertension · Cornerstone Chapter — From Blood Pressure Management to Root-Cause Innovation”. The session is hosted by Prof. Gang Wu, Shanghai General Hospital, and co-hosted by Prof. Dongying Zhang, The First Affiliated Hospital of Chongqing Medical University. Quest for Truth is honored to welcome two distinguished guest speakers: Prof. Xiangqing Kong, The First Affiliated Hospital with Nanjing Medical University; and Prof. Alberto P. Avolio, Macquarie University, Australia.
The roundtable focuses on how hypertension care may evolve from numerical blood pressure control toward mechanism-based and precision-oriented management. The experts discuss the limitations of lifelong medication, the low global control rate of hypertension, central nervous system regulation, perirenal adipose tissue as a potential therapeutic target, arterial stiffness and hemodynamic mechanisms, cuffless and wearable blood pressure monitoring, clinical validation standards, and the future role of Chinese innovation in reshaping global hypertension treatment.
In this segment, Prof. Xiangqing Kong explains how his team identified perirenal adipose tissue as an unconventional therapeutic target in hypertension. He describes specialized ADCs cells within perirenal fat that may stimulate afferent nerve signaling, transmitting abnormal signals through the DRG to the central nervous system and contributing to the development and maintenance of hypertension.
Prof. Kong further introduces his team’s non-invasive focused ultrasound approach, designed to interrupt this afferent nerve “highway” through a one-time outpatient intervention. By targeting both sides of the lower perirenal region, the therapy aims to reduce excessive stimulation to the central nervous system while preserving surrounding tissue, offering a potential mechanism-based pathway for future hypertension treatment.